Knight Therapeutics Announces Regulatory Submission of GEMTESA® in Canada
MONTREAL, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") TSX:GUD, a pan-American (ex-US) pharmaceutical company, announced today that Knight’s New Drug Submission (NDS) for GEMTESA® (vibegron), proposed for the treatment of overactive bladder (OAB) with symptoms of urge urin…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.